长江生命科技(00775.HK):将展示黑色素瘤抗原疫苗免疫疗法研究之临床数据
长江生命科技(00775.HK)公布,旗下美国全资附属公司Polynoma将在美国临床肿瘤学会(ASCO)於今年5月29日至31日在网上举行的ASCO20虚拟科学年会上,展示其基於黑色素瘤抗原疫苗免疫疗法研究(Melanoma Antigen Vaccine Immunotherapy Study,为seviprotimut-L第三阶段临床研究)B1部分所得临床数据而作出的最终分析。研究摘要经选定为黑色素瘤/皮肤癌壁报讨论环节中进行讨论的12项摘要之一。
Polynoma认为黑色素瘤抗原疫苗免疫疗法研究B1部分的最终分析,进一步确定去年中期分析的所得结果,显示使用seviprotimut-L後第二B/二C期黑色素瘤患者(尤其是60岁以下患者及溃疡病患者)之无复发存活期较长。
在ASCO20虚拟科学年会上展示的数据,乃来自对Polynoma现正进行seviprotimut-L第三阶段临床试验B1部分所招募347名患者的数据进行的最终分析。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.